|New lab - Shelton CT|
EbolaCide2 - Plan of attack
Corinne (Scully) is gone and Gene (Olinger) is at the NIH virology labs
I'm in touch with Gene and would love to work with him.
We're shooting for a mid-November ship date but that's completely dependent on completing the synthesis of all the variants. Usually we make 8 variants, send them for testing, take the best two, expand them and make another eight.
This time, we're making many more and they'll all be tested during the same pass to save time.
If this works as we hope, I want to get EbolaCide to Africa ASAP!
EUGENE SEYMOUR - Chief Executive Officer & Director
October 31, 2014
Present - bench top model:
New lab - walk-in hood about 10 feet high:
Dr. Diwan, President NNVC and inventor explains the underlying newly patented technology and other NNVC licensed patent applications
NanoViricides, Inc. (NNVC)
A typical nanoviricides drug is designed like a chemical missile. It has a number of recognition "ligands" on its surface, that are specific to a single type of virus, say HIV. They are like the GPS on a directed missile. They will identify the enemy and attach to specific "landing sites" on the enemy target. The nanoviricides drug, after landing, spreads itself all over the virus particle, and thus completely neutralizes and disables the virus particle from binding to its target, a human cell.
Market Cap: $263.38
Shares Outstanding: 42.76
NanoViricides CEO's Letter to Shareholders, March 11, 2014
Officers and Executives
Solubilization and Targeted Delivery of Drugs with Selfassembling Amphiphilic PolymersOral administration
Antibody response with Oral administration was stronger than that with IV administration.
Home Page: nanoviricides.com
Investor Relations: nanoviricides.com
Corporate History/Profile: nanoviricides.com
NanoViricides Inc Group Headquarters: SUITE 205, 135 WOOD STREET, WEST HAVEN, CT 06516, United States
Vecoy Nanomedicines Ltd.
NanoViricides Announces Initiation of Toxicology Study of FluCide®